Acute coronary syndrome associated with phencyclidine use

Hakeem Ayinde, Robert Solomon, Maria-Elise Sanchez, James Diggs, Prafulla Mehrotra

ABSTRACT

Introduction: Many studies have documented the deleterious effects of psychoactive substances like cocaine and amphetamines on the coronary vasculature. However, the impact of phencyclidine (PCP) on the arteries of the heart has largely gone unrecorded.

Case Report: We report a case of a 41-year-old female presented to our hospital with chest heaviness, shortness of breath, and nausea, which started at rest and lasted about 30 minutes. Her symptoms resolved on arrival to the emergency room. Electrocardiogram showed transient T wave inversions in V2 and V3 leads, and troponins peaked at 1.01 ng/ml 6 hours after arrival. She received standard therapy for non-ST elevation myocardial infarction. An urgent cardiac catheterization revealed severe vasospasm in 3 cm length of the proximal left anterior descending artery, and milder vasospasm in the mid-portion of the artery; spasm resolved after multiple doses of intracoronary nitroglycerin. We excluded the presence of common precipitants of coronary vasospasm. However, the patient admitted to phencyclidine use about two hours prior to the onset of symptoms, and a urine toxicology screen was positive only for the drug. Given the strong temporal relationship of symptoms to PCP use and absence of common precipitants of coronary vasospasm, we concluded that her coronary spasms were induced by PCP.

Conclusion: We describe a case of acute coronary syndrome in a low risk patient thought to be induced by PCP. Our case illustrates the need for physicians to be aware of PCP ingestion as a possible cause of coronary artery spasm when presented with a young adult patient suffering from acute coronary syndrome.
Acute coronary syndrome associated with phencyclidine use

Hakeem Ayinde, Robert Solomon, Maria-Elise Sanchez, James Diggs, Prafulla Mehrotra

ABSTRACT

Introduction: Many studies have documented the deleterious effects of psychoactive substances like cocaine and amphetamines on the coronary vasculature. However, the impact of phencyclidine (PCP) on the arteries of the heart has largely gone unrecorded. Case report: We report a case of a 41-year-old female presented to our hospital with chest heaviness, shortness of breath, and nausea, which started at rest and lasted about 30 minutes. Her symptoms resolved on arrival to the emergency room. Electrocardiogram showed transient T wave inversions in V2 and V3 leads, and troponins peaked at 1.01 ng/ml 6 hours after arrival. She received standard therapy for non-ST elevation myocardial infarction. An urgent cardiac catheterization revealed severe vasospasm in 3 cm length of the proximal left anterior descending artery, and milder vasospasm in the mid-portion of the artery; spasm resolved after multiple doses of intracoronary nitroglycerin.

We excluded the presence of common precipitants of coronary vasospasm. However, the patient admitted to phencyclidine use about two hours prior to the onset of symptoms, and a urine toxicology screen was positive only for the drug. Given the strong temporal relationship of symptoms to PCP use and absence of common precipitants of coronary vasospasm, we concluded that her coronary spasms were induced by PCP. Conclusion: We describe a case of acute coronary syndrome in a low risk patient thought to be induced by PCP. Our case illustrates the need for physicians to be aware of PCP ingestion as a possible cause of coronary artery spasm when presented with a young adult patient suffering from acute coronary syndrome.

Keywords: Chest pain, Coronary vasospasm, Phencyclidine

INTRODUCTION

Phencyclidine (PCP), a synthetic compound originally intended to be used as an anesthetic drug, has been abused throughout the United States for several decades. Its prevalent use has especially been noted in Washington DC where in 2012, up to 12% of male arrestees tested positive for the drug, compared to a 1% rate in other major cities in the country [1]. While PCP is principally noted for its
hallucinogenic effects, it has also been reported to cause such cardiovascular effects as tachycardia, hypertension, and rarely cardiac arrest [2]. Even though animal studies have implicated PCP as a cause of coronary vasospasm, this has not been documented in humans to the best of our knowledge.

We discuss the case of a young adult woman at low risk for coronary artery disease, who presented with acute coronary syndrome due to coronary vasospasm in the setting of acute PCP ingestion.

CASE REPORT

A 41-year-old African American woman presented to the emergency department complaining of chest heaviness, palpitations, shortness of breath, and nausea at rest, which lasted about 30 minutes. She had two similar episodes in the previous month, and these resolved without therapy. Her only cardiovascular risk factor was smoking of a one-fourth pack of cigarettes per day. Her current medications included only vitamins and iron. Symptoms had improved on arrival to the emergency room, and vital signs were within normal limits with a blood pressure of 105/58 mmHg and pulse rate of 85 beats/minute. Physical examination was normal. Electrocardiogram showed transient T wave inversion in both leads V2 and V3 (Figure 1). Laboratory studies revealed rising troponin levels that peaked at 1.01 ng/ml 6 hours after arrival. She was diagnosed with non-ST elevation MI and given standard therapy of aspirin, clopidogrel, and enoxaparin, and she was subsequently prepared for urgent coronary angiography.

Coronary angiography revealed severe vasospasm in 3 cm length of the proximal left anterior descending artery, as well as a milder vasospasm in the mid-portion of the vessel (Figure 2A). Three doses of 200 µg intracoronary nitroglycerin were needed to relieve the vasospasm, after which there were no areas of flow-limiting stenosis identifiable in the coronary arteries (Figure 2B). Further history revealed PCP ingestion about 2 hours prior to the onset of symptoms, and a urine drug screen was positive only for phencyclidine. The patient was discharged on sublingual nitroglycerin as needed, and advised to avoid PCP and other drugs of abuse in the future.

DISCUSSION

To the best of our knowledge, this is the first reported association between PCP ingestion and acute coronary syndrome. Our patient was a young adult woman at low risk for coronary artery disease who presented with chest pain at rest and was found to have severe coronary spasm that was reversed by nitroglycerin during angiography. Urine toxicology screen was positive for PCP, but negative for other stimulants such as cocaine or amphetamine. We considered and excluded other common triggers for coronary spasm (Table 1) [3, 4]. She had a history of cigarette smoking but she did not smoke any cigarettes prior to onset of symptoms on the day she presented. We suggest that the coronary vasospasm may have been caused by PCP ingestion since her symptoms started only about 2 hours after smoking PCP.

PCP (1-(1-phenylcyclohexyl)piperidine hydrochloride) is a noncompetitive NMDAR (N-methyl-D-aspartate receptor) antagonist initially introduced in the 1950s as a dissociative anesthetic agent but withdrawn because of its prolonged unmanageable side effects [5]. It is now a commonly abused street drug in major US cities, especially Washington DC [1].

The major cardiovascular effects in cases of PCP toxicity are hypertension and tachycardia [2], probably due to the inhibition of neuronal catecholamine reuptake or potentiation of noradrenaline release [6].

Although undocumented in humans, animal studies have demonstrated the effects of PCP on coronary vasculature [7–10]. In vitro, PCP appeared to have a vasoconstrictive effect on the coronary arteries in pigs and dogs. It also caused a reversible reduction of coronary blood flow in guinea pigs [7–10]. While PCP induced a paradoxical increase in coronary blood flow in dogs, a simultaneous ECG recording showed that ischemic changes were present [10]. The effects of PCP on the coronaries were inhibited by detromethorphan, a direct
inhibitor of the PCP receptor [7]. This suggests that PCP may act directly on receptors in animal coronary arteries.

Recent data on PCP effects in humans is not extensive most likely because it is not a widely prevalent drug of abuse [1], and because its clinical use has been discontinued for many years. Additionally, many street drug abusers ingest multiple drugs, and thus there may be confounding effects of these drugs if their activity and pharmacokinetics are not well known. For example, up to 34% of male arrestees in major US cities tested positive for multiple drugs in 2012 [1].

The closest drug to PCP that is in clinical use is Ketamine (2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one). Ketamine is a structural analogue of PCP with similar effects but less toxicity, and it is used as a dissociative sedative for brief procedures, particularly in children. The side effects of ketamine and PCP are similar at toxic doses, and in addition, the former has been associated with chest pain when used for analgesia or as a drug of abuse.

Our patient developed chest pain two hours after smoking PCP. We acknowledge that the temporal relationship does not prove PCP as the culprit. However, evidence from animal studies and reports on ketamine (a structural analogue of PCP) use in humans support the suggestion of PCP as the precipitant of coronary spasm in our patient.

## CONCLUSION

Although there is paucity of data in humans, phencyclidine (PCP) has been shown to cause vasoconstriction and reduction in coronary blood flow in animal models. Additional studies are needed to confirm the effects of the drug on the human coronary artery. Our case illustrates the need for physicians to be aware of PCP ingestion as a possible cause of coronary artery spasm in young adult patients presenting with acute coronary syndrome.

Acknowledgements

We acknowledge the suggestions of R. F. Gillum, MD, MS and Adedayo Ogunleye, DO.

Author Contributions

Hakeem Ayinde – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Robert Solomon – Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Maria-Elise Sanchez – Acquisition of data, Analysis and interpretation of data, Drafting the article, Final approval of the version to be published

James Diggs – Acquisition of data, Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published

Prafulla Mehrotra – Substantial contributions to conception and design, Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor

The corresponding author is the guarantor of submission.

Conflict of Interest

Authors declare no conflict of interest.

Copyright

© 2015 Hakeem Ayinde et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
REFERENCES

1. ADAM II 2012 annual report. [Available at: http://www.whitehouse.gov/sites/default/files/ondcp/policy-and-research/adam_ii_2012_annual_rpt_web.pdf. Accessed February 1, 2015]

2. McCarron MM, Schulze BW, Thompson GA, Conder MC, Goetz WA. Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. Ann Emerg Med 1981 May;10(5):237–42.

3. Aniline O, Pitts FN Jr. Phencyclidine (PCP): a review and perspectives. Crit Rev Toxicol 1982 Apr;10(2):145–77.

4. Ilett KF, Jarrott B, O'Donnell SR, Wanstall JC. Mechanism of cardiovascular actions of 1-(1-phenylcyclohexyl)piperidine hydrochloride (phencyclidine). Br J Pharmacol Chemother 1966 Oct;28(1):73–83.

5. Shi GG, Xu SF. Phencyclidine receptors in porcine coronary artery.

6. Shi GG, Xu SF. Effect of phencyclidine on contraction of porcine coronary vessel strips. Zhongguo Yao Li Xue Bao 1993 Jan;14(1):39–41.

7. Shi GG, Xu SF. Effect of phencyclidine on coronary artery flow in the isolated heart of the guinea-pig. Acta Acad Med Shanghai 1994;21:93–6.

8. Shi GG, Wei DS, Liu BJ, Xu SF. Effect of phencyclidine on dog coronary artery. Zhongguo Yao Li Xue Bao 1996 May;17(3):224–6.

9. Weiner AL, Vieira L, McKay CA, Bayer MJ. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 2000 May;18(4):447–51.

10. Ward J, Standage C. Angina pain precipitated by a continuous subcutaneous infusion of ketamine. J Pain Symptom Manage 2003 Jan;25(1):6–7.
Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.

Most Favored Author program
Join this program and publish any number of articles free of charge for one to five years.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US

Edorium Journals: On Web
Browse Journals

This page is not a part of the published article. This page is an introduction to Edorium Journals and the publication services.